ImmunityBio, Inc. IBRX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s additional paid-in capital?
- ImmunityBio, Inc. (IBRX) reported additional paid-in capital of $3.46B in Q1 2026.
- How has ImmunityBio, Inc.'s additional paid-in capital changed year-over-year?
- ImmunityBio, Inc.'s additional paid-in capital increased by 19.6% year-over-year, from $2.89B to $3.46B.
- What is the long-term trend for ImmunityBio, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s additional paid-in capital has grown at a 16.4% compound annual growth rate (CAGR), from $1.5B to $3.2B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.